| Description |
BAY-390 is a selective, across species active and brain penetrating TRPA1 inhibitor. BAY-390 inhibits hTRPA1 FLIPR, hTRPA1 Ephys, rTRPA1 FLIPR and rDRG Ephys with IC50s of 16, 82, 63 and 35 nM, respectively. BAY-390 can be used for the research of inflammation[1].
|
| Related Catalog |
|
| Target |
IC50: 16 nM (hTRPA1 FLIPR), 82 nM (hTRPA1 Ephys), 63 nM (rTRPA1 FLIPR), 35 nM (rDRG Ephys), 73 nM (mTRPA1), 68 nM (gpTRPA1), 81 nM (dogTRPA1)m, 19 nM (monkeyTRPA1)[1]
|
| In Vitro |
BAY-390 inhibits hTRPA1 FLIPR, hTRPA1 Ephys, rTRPA1 FLIPR and rDRG Ephys with IC50s of 16, 82, 63 and 35 nM, respectively[1]. BAY-390 inhibits mTRPA1, gpTRPA1, dogTRPA1 and monkeyTRPA1 with IC50s of 73, 68, 81 and 19 nM, respectively[1].
|
| In Vivo |
BAY-390 (30 and 90 mg/kg; p.o.; BID for 10 days) effects the neuropathic pain in vivo[1]. BAY-390 reduces visceral pain in rat cyclophosphamide induced cystitis models[1]. BAY-390 shows efficacy in inflammatory pain and neurogenic inflammation models[1]. Animal Model: Nrodent animals with neuropathic pain[1] Dosage: 30 and 90 mg/kg Administration: Oral gavage; 30 and 90 mg/kg; twice daily for 10 days Result: Effectively reduced the neuropathic pain in rodent neuropathic pain model.
|
| References |
[1].
|
